Second-line treatment options for advanced lung cancer after immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This study looks at different treatment choices for patients with advanced non-small cell lung cancer (a common type of lung cancer) whose disease got worse despite receiving immunotherapy (a type of drug that helps the immune system fight cancer) as their first treatment. The goal is to understand which second-line treatments work best for these patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or metastatic non-small cell lung cancer (NSCLC) that cannot be cured
- Your cancer was confirmed by a biopsy or cell sample (not just imaging)
- You received at least 3 cycles of immunotherapy (checkpoint inhibitor drugs) as your first treatment
- Your cancer got worse while you were on that first immunotherapy treatment
- You have complete medical records including your smoking history, tumor location, and imaging scans
- You are able to continue treatment without factors that might cause you to stop early
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
This study looks at patients with advanced non-small cell lung cancer who received immunotherapy (immune checkpoint inhibitors) alone or in combination with other treatments. It aims to understand why some patients survive longer than others by analyzing their medical data and using AI to predict outcomes.
This trial tests a three-drug combination (nab-paclitaxel, lenvatinib, and pembrolizumab) as a second-line treatment for people with advanced non-small cell lung cancer that has worsened after initial immunotherapy and chemotherapy. It aims to see if this combination can help control the cancer when first-line treatment stops working.
This study looks at genetic information from tumor tissue of people with non-small cell lung cancer who had immunotherapy before surgery but still had some cancer cells left. The goal is to understand why the cancer did not completely respond to treatment.
This study looks at how well immunotherapy works for people with advanced non-small cell lung cancer who have not received treatment yet and whose tumors do not have a protein called PD-L1. It aims to understand their health outcomes and the effects of the treatment.
This trial tests how well immunotherapy works as a first treatment for advanced lung squamous cell carcinoma, either alone or with chemotherapy. It aims to see if this approach can help patients who haven't had prior cancer treatment.
Hear when a new Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.